Precipio (PRPO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting will be held virtually on June 15, 2026, with stockholders able to participate and vote online using a 16-digit control number.
Proxy materials and the 2025 Annual Report are available online, with options for electronic or paper delivery.
Only stockholders of record as of April 21, 2026, are entitled to vote at the meeting.
Voting can be done by mail, phone, internet, or during the virtual meeting, with detailed instructions provided.
Voting matters and shareholder proposals
Proposal One: Election of Richard Sandberg, Christina Valauri, and Jeffrey Cossman, M.D. as Class II directors for terms expiring in 2029.
Proposal Two: Ratification of CBIZ CPAs, P.C. as the independent registered public accounting firm for the year ending December 31, 2026.
Shareholders may submit additional proposals for future meetings, with deadlines and requirements specified.
Board of directors and corporate governance
The board consists of seven directors divided into three classes, with staggered three-year terms.
All directors except the CEO are independent; committees are fully independent.
Board diversity is emphasized, considering gender, race, experience, and skills.
The chairperson role is separated from the CEO to enhance governance.
Directors attended 100% of board and committee meetings in 2025.
Latest events from Precipio
- Rapid, profitable growth driven by innovative four-hour diagnostics and scalable operations.PRPO
Planet MicroCap Las Vegas 202617 Jun 2026 - All director nominees and the independent auditor were approved by shareholder vote.PRPO
AGM 202616 Jun 2026 - Q1 revenue up 36% YoY; shipment delays, CMS cuts, and losses drive ongoing going concern risks.PRPO
Q1 202619 May 2026 - Director elections and auditor ratification headline the June 2026 annual meeting agenda.PRPO
Proxy filing28 Apr 2026 - Positive cash flow and 30% revenue growth in 2025 set the stage for accelerated product expansion.PRPO
Q4 20252 Apr 2026 - Q2 2025 net sales up 27%, gross margin at 43%, with positive net income but ongoing risks.PRPO
Q2 202527 Jan 2026 - Q1 2025 revenue up 44% to $4.9M, gross margin 43%, net loss narrowed, but risks remain.PRPO
Q1 202527 Jan 2026 - Q3 2025 saw 30% revenue growth, positive EBITDA, 44% margin, but going concern risk persists.PRPO
Q3 202527 Jan 2026 - Net sales and pathology revenues rose, but losses and liquidity concerns remain.PRPO
Q3 202427 Jan 2026